Selumetinib plus docetaxel shows KRAS-mutant NSCLC potential

The addition of selumetinib to docetaxel therapy may boost the survival of patients with KRAS-mutant non-small-cell lung cancer, suggest study findings published in The Lancet Oncology.

via Med Wire News